Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: pramlintide acetate

« Back to Dashboard
Pramlintide acetate is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and eighteen patent family members in twenty-five countries.

There are two drug master file entries for pramlintide acetate. Two suppliers are listed for this compound.

Summary for Generic Name: pramlintide acetate

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers: see list2
Therapeutic Class:Blood Glucose Regulators

Pharmacology for Ingredient: pramlintide acetate

Drug ClassAmylin Analog
Mechanism of ActionAmylin Agonists

Clinical Trials for: pramlintide acetate

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
Status: Completed Condition: Overweight; Obesity

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Status: Completed Condition: Obesity

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
Status: Completed Condition: Overweight; Obesity

A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
Status: Completed Condition: Type 1 Diabetes Mellitus

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes
Status: Completed Condition: IDDM

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
Status: Completed Condition: Obesity

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
Status: Active, not recruiting Condition: Type 1 Diabetes

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes
Status: Withdrawn Condition: Type 1 Diabetes

Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
Status: Completed Condition: Type 1 Diabetes

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
Status: Completed Condition: Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
You have an error in your SQL syntax; check the manual that corresponds to your MySQL server version for the right syntax to use near 'LIMIT 5' at line 4